Cell-based delivery of oncolytic viruses: A new strategic alliance for a biological strike against cancer

Molecular Therapy

Volumn 15, Issue 4, 2007, Pages 660-665

  Power, Anthony T ^a   Bell, John C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ONCOLYTIC VIRUS;

BLOOD CELL; CANCER; CANCER CELL; CANCER GENE THERAPY; CANCER INHIBITION; CELL BASED GENE THERAPY; CELL DEATH; CELL FUSION; CELL IMMORTALIZATION; CELL LINE; CELL LINEAGE; CELLULAR IMMUNITY; HERPES SIMPLEX; IMMUNOSTIMULATION; KILLER CELL; MEASLES VIRUS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ONCOLYTIC VIROTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; RETROVIRUS; REVIEW; STEM CELL; T LYMPHOCYTE; TRANSGENE; VIRAL GENE THERAPY; VIRUS REPLICATION;

ANIMALS; CELL LINE; HUMANS; KILLER CELLS; MESENCHYMAL STEM CELLS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; T-LYMPHOCYTES;

EID: 33947190925     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300098     Document Type: Review

References (66)

1. Lecoq, H (2001). Discovery of the first virus, the tobacco mosaic virus: 1892 or 1898? C R Acad Sci III 324: 929-933.
2. DePace, N (1912). Sulla scomparsa di un enorme vegetante del collo dell'utero senza cura chirugica cancro. La Ginecologia 9: 82-88.
3. Parato, KA, Senger, D, Forsyth, PA and Bell, JC (2005). Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 5: 965-976.
4. Yu, YA, Shabahang, S, Timiryasova, TM, Zhang, Q, Beltz, R and Gentschev, I et al. (2004). Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 22: 313-320.
5. Phuong, LK, Allen, C, Peng, KW, Giannini, C, Greiner, S and TenEyck, CJ et al. (2003). Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 63: 2462-2469.
6. Stojdl, DF, Lichty, BD, tenOever, BR, Paterson, JM, Power, AT and Knowles, S et al. (2003). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275.
7. Power, AT, Wang, J, Falls, TJ, Paterson, JM, Parato, KA and Lichty, BD et al. Cell-based delivery of an oncolytic virus circumvents anti-viral immunity. Mol Ther 15: 123-130.
8. Ikeda, K, Ichikawa, T, Wakimoto, H, Silver, JS, Deisboeck, TS and Finkelstein, D et al. (1999). Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 5: 881-887.
9. Wakimoto, H, Ikeda, K, Abe, T, Ichikawa, T, Hochberg, FH and Ezekowitz, RA (2002). The complement response against an oncolytic virus is species-specific in its activation pathways. Mol Ther 5: 275-282.
10. Chen, Y, Yu, DC, Charlton, D and Henderson, DR (2000). Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy. Hum Gene Ther 11: 1553-1567.
11. Tsai, V, Johnson, DE, Rahman, A, Wen, SF, LaFace, D and Philopena, J et al. (2004). Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model. Clin Cancer Res 10: 7199-7206.
12. Ong, HT, Hasegawa, K, Dietz, AB, Russell, SJ and Peng, KW (2006). Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther, advance online publication, 19 October 2006.
13. Hirasawa, K, Nishikawa, SG, Norman, KL, Coffey, MC, Thompson, BG and Yoon, CS et al. (2003). Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 63: 348-353.
14. Lang, SI, Giese, NA, Rommelaere, J, Dinsart, C and Cornelis, JJ (2006). Humoral immune responses against minute virus of mice vectors. J Gene Med 8: 1141-1150.
15. Takeuchi, Y, Cosset, FL, Lachmann, PJ, Okada, H, Weiss, RA and Collins, MK (1994). Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol 68: 8001-8007.
16. Iankov, I, Blechacz, B, Liu, C, Schmeckpeper, JD, Tarara, JE and Federspiel, MJ et al. Infected cell carriers_a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther 15: 114-122.
17. Lyons, M, Onion, D, Green, NK, Aslan, K, Rajaratnam, R and Bazan-Peregrino, M et al. (2006). Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther 14: 118-128.
18. Worgall, S, Wolff, G, Falck-Pedersen, E and Crystal, RG (1997). Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 8: 37-44.
19. Ye, X, Jerebtsova, M and Ray, PE (2000). Liver bypass significantly increases the transduction efficiency of recombinant adenoviral vectors in the lung, intestine, and kidney. Hum Gene Ther 11: 621-627.
20. Dudley, ME and Rosenberg, SA (2003). Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3: 666-675.
21. Yee, C, Riddell, SR and Greenberg, PD (2001). In vivo tracking of tumor-specific T cells. Curr Opin Immunol 13: 141-146.
22. Cole, C, Qiao, J, Kottke, T, Diaz, RM, Ahmed, A and Sanchez-Perez, L et al. (2005). Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat Med 11: 1073-1081.
23. Lu, PH and Negrin, RS (1994). A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153: 1687-1696.
24. Baker, J, Verneris, MR, Ito, M, Shizuru, JA and Negrin, RS (2001). Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 97: 2923-2931.
25. Verneris, MR, Karami, M, Baker, J, Jayaswal, A and Negrin, RS (2004). Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103: 3065-3072.
26. Edinger, M, Cao, YA, Verneris, MR, Bachmann, MH, Contag, CH and Negrin, RS et al. (2003). Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 101: 640-648.
27. Thorne, SH, Negrin, RS and Contag, CH (2006). Synergistic antitumor effects of immune cell-viral biotherapy. Science 311: 1780-1784.
28. Prockop, DJ (1997). Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276: 71-74.
29. Studeny, M, Marini, FC, Dembinski, JL, Zompetta, C, Cabreira-Hansen, M and Bekele, BN et al. (2004). Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96: 1593-1603.
30. Komarova, S, Kawakami, Y, Stoff-Khalili, MA, Curiel, DT and Pereboeva, L (2006). Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 5: 755-766.
31. Lyden, D, Hattori, K, Dias, S, Costa, C, Blaikie, P and Butros, L et al. (2001). Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7: 1194-1201.
32. Gehling, UM, Ergun, S, Schumacher, U, Wagener, C, Pantel, K and Otte, M et al. (2000). In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 95: 3106-3112.
33. Lin, Y, Weisdorf, DJ, Solovey, A and Hebbel, RP (2000). Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 105: 71-77.
34. Peichev, M, Naiyer, AJ, Pereira, D, Zhu, Z, Lane, WJ and Williams, M et al. (2000). Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95: 952-958.
35. Quirici, N, Soligo, D, Caneva, L, Servida, F, Bossolasco, P and Deliliers, GL (2001). Differentiation and expansion of endothelial cells from human bone marrow CD133(+) cells. Br J Haematol 115: 186-194.
36. Jevremovic, D, Gulati, R, Hennig, I, Diaz, RM, Cole, C and Kleppe, L et al. (2004). Use of blood outgrowth endothelial cells as virus-producing vectors for gene delivery to tumors. Am J Physiol Heart Circ Physiol 287: H494-H500.
37. Coukos, G, Makrigiannakis, A, Kang, EH, Caparelli, D, Benjamin, I and Kaiser, LR et al. (1999). Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res 5: 1523-1537.
38. Garcia-Castro, J, Martinez-Palacio, J, Lillo, R, Garcia-Sanchez, F, Alemany, R and Madero, L et al. (2005). Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors. Cancer Gene Ther 12: 341-349.
39. Raykov, Z, Balboni, G, Aprahamian, M and Rommelaere, J (2004). Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases. Int J Cancer 109: 742-749.
40. Chambers, AF, Groom, AC and MacDonald, IC (2002). Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572.
41. Raez, LE, Cassileth, PA, Schlesselman, JJ, Sridhar, K, Padmanabhan, S and Fisher, EZ et al. (2004). Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol 22: 2800-2807.
42. Nemunaitis, J, Jahan, T, Ross, H, Sterman, D, Richards, D and Fox, B et al. (2006). Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther 13: 555-562.
43. Bowman, LC, Grossmann, M, Rill, D, Brown, M, Zhong, WY and Alexander, B et al. (1998). Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther 9: 1303-1311.
44. Bowman, L, Grossmann, M, Rill, D, Brown, M, Zhong, WY and Alexander, B et al. (1998). IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 92: 1941-1949.
45. Tartour, E, Mehtali, M, Sastre-Garau, X, Joyeux, I, Mathiot, C and Pleau, JM et al. (2000). Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings. Br J Cancer 83: 1454-1461.
46. Rochlitz, C, Dreno, B, Jantscheff, P, Cavalli, F, Squiban, P and Acres, B et al. (2002). Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: Phase II randomized study comparing two dose levels. Cancer Gene Ther 9: 289-295.
47. Ram, Z, Culver, KW, Oshiro, EM, Viola, JJ, DeVroom, HL and Otto, E et al. (1997). Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3: 1354-1361.
48. Hallden, G, Hill, R, Wang, Y, Anand, A, Liu, TC and Lemoine, NR et al. (2003). Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol Ther 8: 412-424.
49. Kim, JH, Oh, JY, Park, BH, Lee, DE, Kim, JS and Park, HE et al. (2006). Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 14: 361-370.
50. Hummel, JL, Safroneeva, E and Mossman, KL (2005). The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma. Mol Ther 12: 1101-1110.
51. Todo, T, Rabkin, SD, Sundaresan, P, Wu, A, Meehan, KR and Herscowitz, HB et al. (1999). Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 10: 2741-2755.
52. Salgaller, ML and Lodge, PA (1998). Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J Surg Oncol 68: 122-138.
53. Gilboa, E (1996). Immunotherapy of cancer with genetically modified tumor vaccines. Semin Oncol 23: 101-107.
54. Pardoll, DM (1995). Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13: 399-415.
55. Huang, Q, Liu, D, Majewski, P, Schulte, LC, Korn, JM and Young, RA et al. (2001). The plasticity of dendritic cell responses to pathogens and their components. Science 294: 870-875.
56. Der, SD, Zhou, A, Williams, BR and Silverman, RH (1998). Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA 95: 15623-15628.
57. Plaksin, D, Porgador, A, Vadai, E, Feldman, M, Schirrmacher, V and Eisenbach, L (1994). Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV). Int J Cancer 59: 796-801.
58. Hallak, LK, Merchan, JR, Storgard, CM, Loftus, JC and Russell, SJ (2005). Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression. Cancer Res 65: 5292-5300.
59. Bergman, I, Whitaker-Dowling, P, Gao, Y and Griffin, JA (2004). Preferential targeting of vesicular stomatitis virus to breast cancer cells. Virology 330: 24-33.
60. Morizono, K, Xie, Y, Ringpis, GE, Johnson, M, Nassanian, H and Lee, B et al. (2005). Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med 11: 346-352.
61. Hasegawa, K, Nakamura, T, Harvey, M, Ikeda, Y, Oberg, A and Figini, M et al. (2006). The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res 12 (Part 1): 6170-6178.
62. Nakamura, T, Peng, KW, Harvey, M, Greiner, S, Lorimer, IA and James, CD et al. (2005). Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 23: 209-214.
63. Bucheit, AD, Kumar, S, Grote, DM, Lin, Y, von Messling, V and Cattaneo, RB et al. (2003). An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther 7: 62-72.
64. Hammond, AL, Plemper, RK, Zhang, J, Schneider, U, Russell, SJ and Cattaneo, R (2001). Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol 75: 2087-2096.
65. Peng, KW, Donovan, KA, Schneider, U, Cattaneo, R, Lust, JA and Russell, SJ (2003). Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood 101: 2557-2562.
66. Wang, GG, Calvo, KR, Pasillas, MP, Sykes, DB, Hacker, H and Kamps, MP (2006). Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8. Nat Methods 3: 287-293.